<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37991997</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1545-861X</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>47</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>24</Day></PubDate></JournalIssue><Title>MMWR. Morbidity and mortality weekly report</Title><ISOAbbreviation>MMWR Morb Mortal Wkly Rep</ISOAbbreviation></Journal><ArticleTitle>Notes from the Field: House-to-House Campaign Administration of Inactivated Poliovirus Vaccine - Sokoto State, Nigeria, November 2022.</ArticleTitle><Pagination><StartPage>1290</StartPage><EndPage>1291</EndPage><MedlinePgn>1290-1291</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.15585/mmwr.mm7247a3</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Biya</LastName><ForeName>Oladayo</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Manu</LastName><ForeName>Jibrin Idris</ForeName><Initials>JI</Initials></Author><Author ValidYN="Y"><LastName>Forbi</LastName><ForeName>Joseph C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Wa Nganda</LastName><ForeName>Gatei</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Ikwe</LastName><ForeName>Hadley</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Sule</LastName><ForeName>Adamu</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Edukugho</LastName><ForeName>Aboyowa</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Shehu</LastName><ForeName>Abba</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Aliyu</LastName><ForeName>Nurudeen</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Barau</LastName><ForeName>Nyampa David</ForeName><Initials>ND</Initials></Author><Author ValidYN="Y"><LastName>Wiesen</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Sutter</LastName><ForeName>Roland W</ForeName><Initials>RW</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>MMWR Morb Mortal Wkly Rep</MedlineTA><NlmUniqueID>7802429</NlmUniqueID><ISSNLinking>0149-2195</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009549" MajorTopicYN="N" Type="Geographic">Nigeria</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Roland W. Sutter reports ownership of 5,000 shares of Pharmajet stock (no value declared). No other potential conflicts of interest were disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>24</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>22</Day><Hour>18</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>22</Day><Hour>13</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37991997</ArticleId><ArticleId IdType="pmc">PMC10685385</ArticleId><ArticleId IdType="doi">10.15585/mmwr.mm7247a3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cooper LV, Bandyopadhyay AS, Gumede N, et al. Risk factors for the spread of vaccine-derived type 2 polioviruses after global withdrawal of trivalent oral poliovirus vaccine and the effects of outbreak responses with monovalent vaccine: a retrospective analysis of surveillance data for 51 countries in Africa. Lancet Infect Dis 2022;22:284–94. 10.1016/S1473-3099(21)00453-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00453-9</ArticleId><ArticleId IdType="pmc">PMC8799632</ArticleId><ArticleId IdType="pubmed">34648733</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox JP. Modes of action of poliovirus vaccines and relation to resulting immunity. Rev Infect Dis 1984;6(Suppl 2):S352–5. 10.1093/clinids/6.Supplement_2.S352</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/clinids/6.Supplement_2.S352</ArticleId><ArticleId IdType="pubmed">6740072</ArticleId></ArticleIdList></Reference><Reference><Citation>Voorman A, Lyons H, Shuab F, et al. Evaluation of novel oral polio vaccine type 2 SIA impact in a large outbreak of circulating vaccine-derived poliovirus in Nigeria. J Infect Dis 2023;jiad222. 10.1093/infdis/jiad222</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad222</ArticleId><ArticleId IdType="pmc">PMC10938209</ArticleId><ArticleId IdType="pubmed">37357964</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand A, Zaman K, Estívariz CF, et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine 2015;33:6816–22. 10.1016/j.vaccine.2015.09.039</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.09.039</ArticleId><ArticleId IdType="pmc">PMC10423714</ArticleId><ArticleId IdType="pubmed">26476367</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullo UF, Mehraj J, Raza SM, et al. An experience of mass administration of fractional dose inactivated polio vaccine through intradermal needle-free injectors in Karachi, Sindh, Pakistan. BMC Public Health 2021;21:44. 10.1186/s12889-020-10041-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-020-10041-8</ArticleId><ArticleId IdType="pmc">PMC7789602</ArticleId><ArticleId IdType="pubmed">33407294</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>